CellMosaic receives Notice of Allowance for Another Patent on NeIon™ molecules

Posted by Yumei Huang on 7th Nov 2016

Woburn, MA, Nov. 7, 2016 – CellMosaic announces today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for the second patent on its proprietary bio-analytical platform technology for specialty diagnostic use (Application No. 15/136,920 entitled “Trifluoroborate Mass Spectrometric Tags”). The granted patent provides intellectual property protection for a broad range of compounds and compositions of organoborates for use in quantitative mass spectroscopy. Unlike mass spectrometric analysis in positive ion mode, analysis in negative ion mode is not common, in part due to a lack of available electronegative groups. There has been an ongoing need for “mass tag” reagents that are suitable for use in negative ion mode mass spectrometry.

“CellMosaic has established the use of organo-trifluoroborates in negative ion mode mass spectrometry, as well as preparation of novel mass-tags for specific analytes. This invention is based on the discovery that organo-trifluoroborates, when subject to fragmentation, such as with collision-induced dissociation (CID), preferentially undergo neutral losses of hydrogen fluoride (HF) or boron trifluoride (BF3), allowing transfer of the negative charge to the rest of the fragment molecule” said Dr. Yumei Huang, founder and CEO of CellMosaic. “We are pleased that the USPTO recognizes our innovation, and look forward to providing the technology to help diagnostic testing applications in support of drug discovery and development.

About CellMosaic, Inc.

CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink™ technologies for studying protein–protein interactions; NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest; super-hydrophilic AqueaTether™ linkers for clean conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqueaTether™ macromolecules for modification of protein/peptide/oligo drugs and the preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving life science communities by providing custom synthesis of high quality bioconjugate products.